We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 3.57% | 14.50 | 14.00 | 15.00 | 15.00 | 14.00 | 14.00 | 1,310,616 | 10:04:36 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -1.74 | 37.78M |
Date | Subject | Author | Discuss |
---|---|---|---|
29/2/2024 10:31 | Next up Angle attending : Next-Gen Immuno-Oncology Conference 07th - 8th March 2024 Park Plaza Victoria London by Radisson, 239 Vauxhall Bridge Rd, Pimlico, London SW1V 1EQ, UK: | gooosed | |
29/2/2024 08:23 | Morning Anglers and chum bucket (you know who you are :(, Interesting couple of days in the wider biopharma sector. Main etf broke out higher a couple of days ago and reached the highest level since early 2022. Instead of selling off since bottoming in mid 2022, it's been a period of stealthy accumulation and a bit under the radar with all the AI stuff. Sector's seen some consolidation with a number of takeovers. Ripe for a decent run to all time highs perhaps. Agl still has some consolidation of it's own but the pressure is building nicely. Think we may still see a spike down before clear out unless news comes fairly soon. | boris cobaka | |
28/2/2024 21:19 | Lol. Why don't we all come back in 6 months and see who was right. Unless of course - there is another agenda... | spa362 | |
28/2/2024 20:57 | Must be an interesting sales pitch with Parsortix to the two major USA certified lab players...We've got this great Parsortix machine it can test for breast cancer and is approved by the FDA well...hmmh...for just one of the twenty four major cancer groups...Now if you are patient and willing to bear the cost of thousands of tests and the time involved you could seek accreditation from the FDA for testing the remaining twenty three cancer groups...Yup expect eyebrows raised and being shown the door pretty darn quick! | bones699 | |
28/2/2024 15:41 | 3pm local (San Diego) time is 11pm GMT. lbx-summit.com/speak A few "household names" present . . . . lbx-summit.com/progr ps. Remove the space after 2nd forward slash | gooosed | |
28/2/2024 13:44 | >>ST no use of Parsortix - shame | toffeeman | |
28/2/2024 12:04 | Let’s ignore the bitter ex employee who can’t explain what they’re doing here :) | adw198 | |
28/2/2024 11:43 | Add.. Yup sure. Cash balance as reported June 2023 £20m monthly burn £1.5m reduced through US lab closure last year 7 months later end Feb 24 I guess at that rate only £8m remaining...They don't have enough cash out to Q2 2025 btw...😉 | bones699 | |
28/2/2024 11:38 | Let's ignore a cash call and also let's ignore the extra £6m revenues promised by Newland and that the business probably won't have enough cash to run to Q1 next year..We can also ignore the impact on share holder dilution from a cash raise..you can kiss goodbye to 16p for starters on that one..but in sole traders world these are just minor issues lol! | bones699 | |
28/2/2024 11:14 | Interesting find ST. | boris cobaka | |
28/2/2024 09:03 | Arthur - have a look at the interim results for the period ended 30 June 2023, dated 7 Sept. I believe 5oleTrader is referring to Angle's corporate partnership with BioView. | jacks13 | |
28/2/2024 08:25 | How's JLP working with your double standards here and on the JLP BB.... Borus? Mighty Shorts from Tiny Acorns (UnModerated) - Post 4788 JLP Jubilee Metals Group Plc 26 Feb 2024 14:05 boris cobaka "The non bias thread is awfully quiet which is understandable I guess. The heads in the sand fascist thread is buzzing with excitement but after their brief fentanyl rns high there's a nasty withdrawal currently underway as the short term collective euphoria quickly dissipates. Drug kingpin Leon may even have hooked a few more. Someone though doesn't appear too content with the current situation. Possibly someone that posts on the thread that's hoping to minimize their exposure. There's certainly some fantastic opportunities elsewhere at the moment and jlp still looks like it hasn't bottomed just yet." | bones699 | |
28/2/2024 08:22 | Agree Boris let's not talk about reality let's just ignore it, pretend it doesn't exist, and copy and paste the demos until the sun goes down..Let's ignore the lack of progress, lack of commercial deals, and lack of money left in the kitty for another day... | bones699 | |
28/2/2024 08:17 | Having established fake bones is very low brow I'm surprised that so many bother to respond to his/her imbecilic comments. It's like one of those wind-up monkeys banging the cymbals (fundraising) continuously with nowt else to say until the clockwork function is exhausted. Just filter the muppet or simply ignore. It's not too difficult. | boris cobaka | |
27/2/2024 22:41 | Yawn...zzzz...when all else fails we can always read your post... | htrocka2 | |
27/2/2024 21:44 | Yawn...zzzz...when all else fails copy and paste cr@p and hope it works out lol! | bones699 | |
27/2/2024 21:10 | https://www.genomewe | toffeeman | |
27/2/2024 20:38 | It's very pertinent to discuss the funding issue as cash balances must surely be just £8m or £9m at most..Cash in June 2023 was £20m with monthly cash burn £1.5m now 7 months on cash is dwindling fast maybe just 6 months left before a cash raise will need to be raised..Newland promised £6m of additional revenues to date nothing delivered and time is marching on as to the 'strategic initiatives' in case cash dried up with no commercial deals in the offing these were just washed over at January's Investor Meet basically fobbing off retail investors...Its looking like another retail drive by mugging by Newland! I reckon we will hear a £20m cash raise announced during Q2 and no later than Q3! | bones699 | |
27/2/2024 14:06 | 5oletrader I don't suppose you could give me a heads up on what you're referring to. I was very ill for much of the last 8 months and am still catching up. | arthur_lame_stocks | |
27/2/2024 13:38 | It keeps getting brought up as an automatic negative. Personally I think it’s fair consider the likelihood and impact of a raise. We’re all here as speculators so it’s a fair topic for the board imo. If you’re not interested about funding thats fine too. As I said my view is it’s not going make or break us, the deals or lack of them will do that. | adw198 | |
27/2/2024 12:38 | This cash call argument is somewhat tiresome - it either happens or it doesn't! Totally out of our control - so position yourself accordingly and have done with it. Let's move on?-We are potentially weeks away from one (1) thing most here seem to have forgotten - CLUE: "The parties are continuing to discuss strategic routes to market with potential corporate partners"What will it bring?Collaborative partnership?Upfront payments?-We should be paying attention when: "Given the significant third-party interest ... it would be the only product-based solution on the market for this purpose"IF you don't know what I'm referring to - then do some research. | 5oletrader | |
27/2/2024 11:09 | Hi, I’m not sure they’ve said they definitely won’t do a raise this year, I thought the gist was more we don’t need to do one this year given the cash runway forecast? They have said there is a gap between hopefully going break even late 2025 and the cash runway ending so a raise seems likely unless they can significantly exceed their own forecasts. Ultimately we need to see some deals land here and that’s what I’m holding for. My hope and expectation is the share price will shoot up as deal(s) are announced and we can raise on better terms with more confidence. | adw198 | |
27/2/2024 10:24 | Details of the summit that Angle will be present at tomorrow | spa362 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions